Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions

被引:148
|
作者
Perez, Lorena [1 ,2 ,3 ]
Munoz-Durango, Natalia [3 ]
Riedel, Claudia A. [1 ,2 ,3 ]
Echeverria, Cesar [4 ]
Kalergis, Alexis M. [3 ,5 ,6 ]
Cabello-Verrugio, Claudio [1 ,2 ,3 ]
Simon, Felipe [1 ,2 ,3 ]
机构
[1] Univ Andres Bello, Fac Ciencias Biol, Dept Ciencias Biol, Ave Republ 239, Santiago 8370134, Chile
[2] Univ Andres Bello, Fac Med, Ave Republ 239, Santiago 8370134, Chile
[3] Millennium Inst Immunol & Immunotherapy, Ave Alameda 340, Santiago 8331150, Chile
[4] Univ Bernardo O Higgins, Lab Bionanotecnol, Gen Gana 1780, Santiago 8370854, Chile
[5] Pontificia Univ Catolica Chile, Fac Med, Dept Reumatol, Ave Alameda 340, Santiago 8331150, Chile
[6] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Genet Mol & Microbiol, Ave Alameda 340, Santiago 8331150, Chile
关键词
TGF-beta; TNE-alpha; Endothelium; Fibrosis; Interleukin; Inflammation; NF-KAPPA-B; TGF-BETA; CARDIAC FIBROSIS; PROGENITOR CELLS; TRANSFORMING GROWTH-FACTOR-BETA-2; PULMONARY-HYPERTENSION; RENAL FIBROSIS; POTENTIAL ROLE; IN-VITRO; PROMOTES;
D O I
10.1016/j.cytogfr.2016.09.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
During the last decade, the endothelial-to-mesenchymal transition (EndMT) process has attracted considerable attention due to associations with the onset of certain diseases, such as organ fibrosis and cancer. Several studies have assessed the mechanisms and signaling pathways that regulate endothelial fibrosis in the context of human pathologies. A number of inflammatory mediators, including pro inflammatory cytokines, growth factors, oxidative stress, and toxins, induce the conversion of endothelial cells into mesenchymal fibroblast-like cells that promote disease progression. This review is separated into five chapters that critically present current knowledge on EndMT in the context of pathology. First, the main characteristics of EndMT are summarized, with a focus on the endothelial protein pattern changes that modulate the expressions of endothelial/fibrotic markers and extracellular matrix proteins. These expressions could serve as mechanisms for explaining potential EndMT contributions to human pathologies in adults. Second, the main findings supporting a connection between EndMT-mediated endothelial fibrosis and inflammatory conditions are presented. These connections could be linked to the onset and progression of pathological conditions. Third, EndMT inducers are described in detail. This includes considerations on the actions of the first and most well-known EndMT inducer, TGF-beta; of the most prominent pro-inflammatory cytokines released during inflammation, such as IL 1-beta and TNF-alpha; and of the NF-kappa B transcription factor, a common player during inflammation-induced EndMT. Furthermore, thorough attention is given to EndMT induction by endotoxins in the context of bacterial infectious diseases. Additionally, the participation of the inflammatory oxidative stress environment in the EndMT induction was also reviewed. Fourth, the pathophysiological findings of inflammation induced EndMT are presented, and, fifth, special focus is placed on associations with cancer onset and development. Altogether, this review highlights the important role of EndMT-mediated endothelial fibrosis during inflammation in human pathologies. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:41 / 54
页数:14
相关论文
共 50 条
  • [21] Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition
    Chen, Xingxing
    Xia, Xue
    Dong, Tiancheng
    Lin, Zhiwei
    Du, Leilei
    Zhou, Hao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 2517 - 2527
  • [22] Endothelial mesenchymal transition in cardiac fibrosis
    Wu, Miao
    Zhang, Sai-Dan
    Peng, Zhen-Yu
    Zhong, Jiang-Hua
    Huang, Kang
    Huang, Li-Hua
    Lu, Shi-Juan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 14950 - 14958
  • [23] Endothelial to mesenchymal transition in kidney fibrosis
    Jacobs, Marleen E.
    de Vries, Dorottya K.
    Engelse, Marten A.
    Dumas, Sebastien J.
    Rabelink, Ton J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (05) : 752 - 760
  • [24] Broadening horizons: molecular mechanisms and disease implications of endothelial-to-mesenchymal transition
    Qian, Cheng
    Dong, Guanglu
    Yang, Chunmei
    Zheng, Weiwei
    Zhong, Chongjin
    Shen, Qiuhong
    Lu, Yin
    Zhao, Yang
    CELL COMMUNICATION AND SIGNALING, 2025, 23 (01)
  • [25] Atheroprone flow enhances the endothelial-to-mesenchymal transition
    Lai, Baochang
    Li, Zhao
    He, Ming
    Wang, Yili
    Chen, Lili
    Zhang, Jiao
    Yang, Yan
    Shyy, John Y-J
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2018, 315 (05): : H1293 - H1303
  • [26] The role of endothelial-to-mesenchymal transition in cancer progression
    Potenta, S.
    Zeisberg, E.
    Kalluri, R.
    BRITISH JOURNAL OF CANCER, 2008, 99 (09) : 1375 - 1379
  • [27] The role of endothelial-to-mesenchymal transition in cancer progression
    S Potenta
    E Zeisberg
    R Kalluri
    British Journal of Cancer, 2008, 99 : 1375 - 1379
  • [28] Vascular Endothelial Growth Factor Prevents Endothelial-to-Mesenchymal Transition in Hypertrophy
    Illigens, Ben M. -W.
    Berazaluce, Alejandra Casar
    Poutias, Dimitrios
    Gasser, Robert
    del Nido, Pedro J.
    Friehs, Ingeborg
    ANNALS OF THORACIC SURGERY, 2017, 104 (03) : 932 - 941
  • [29] Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis
    Chen, Pei-Yu
    Schwartz, Martin A.
    Simons, Michael
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
  • [30] Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching
    Murugavel, Shamini
    Bugyei-Twum, Antoinette
    Matkar, Pratiek N.
    Al-Mubarak, Husain
    Chen, Hao H.
    Adam, Mohamed
    Jain, Shubha
    Narang, Tanya
    Abdin, Rawand M.
    Qadura, Mohammad
    Connelly, Kim A.
    Leong-Poi, Howard
    Singh, Krishna K.
    FRONTIERS IN PHARMACOLOGY, 2018, 9